The abstract is read at the publisher; the summary is JClub's.
In six patients with severe, treatment-refractory ACPA-positive rheumatoid arthritis, mivocabtagene autoleucel produced CD19+ B-cell depletion with CRS limited to grade 1–2.
- Why it matters: Autoimmune RA remains difficult to treat after failure of standard disease-modifying therapies, and early safety/efficacy data are needed for CD19 CAR T approaches.
- What they did: In the nonrandomized phase 1 part of the COMPARE trial, six patients received a single infusion of autologous fully human CD19 CAR T cells after stopping DMARDs and standard lymphodepletion, with follow-up for 36–52 weeks.
- The result: CRS occurred in all patients but no ICANS or serious AEs occurred; one dose-limiting toxicity was grade 3 transaminase elevation, and disease activity improved with a median 34% DAS28-CRP reduction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.